Merck KGaA, with phase 3 data on the horizon, showcases durability of evobrutinib in multiple sclerosis
https://www.fiercebiotech.com/biotech/merck-kgaa-phase-3-data-horizon-showcases-durability-evobrutinib-multiple-sclerosis
Medical Innovation Exchange @ Copywrite 2021. All Rights Reserved.